

Application Serial No. 10/005,646
Attorney Docket No. 51835AUSM1
Response to Office Action of 17 March 2004

APPENDIX

(clean copy of pending Claims 36-41 and 69 as amended herein)

36. (Once Amended) A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by multiple sclerosis, comprising administering to a patient in need thereof an effective amount of an FGF-9 polypeptide or a biologically active fragment thereof.

37. The method of Claim 36, wherein said FGF-9 polypeptide is human.

38. The method of Claim 37, wherein said polypeptide has FGF-9 specific immunogenic activity.

39. (Once Amended) The method of Claim 36, wherein said polypeptide comprises amino acid 1 to amino acid 208 of human FGF-9 as set forth in Fig. 3 (SEQ ID NO: 5).

40. (Once Amended) The method of Claim 36, wherein said polypeptide has 94% sequence identity to amino acid 1 to amino acid 208 of human FGF-9 as set forth in Fig. 3 (SEQ ID NO: 5), and wherein said polypeptide has FGF activity.

41. (Once Amended) The method of Claim 37, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 208 of human FGF-9 as set forth in Fig. 3 (SEQ ID NO: 5), and wherein said polypeptide has FGF activity.

60. The method of claim 36 to treat multiple sclerosis.